Annual Report 2022 17 The proportion of remuneration linked to performance and the fixed proportion are as follows: Fixed remuneration At risk - STI At risk - LTI Name 2022 2021 2022 2021 2022 2021 Directors: Mr. Frederic Bart 100% 3% - - - 97% Dr. Graham Kelly 100% 100% - - - - Mr. Peter Marks 100% 100% - - - - Mr. Boris Patkin 43% 85% - - 57% 15% Dr. Gisela Mautner (appointed 1 February 2022) 27% - - - 73% - Dr. Ian Dixon (resigned 1 August 2020) - 100% - - - - Other Key Management Personnel: Mr. David Franks - - - - - 100% Service agreements Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows: Name: Dr. Gisela Mautner Title: Chief Executive Officer and Managing Director Agreement commenced: 1 February, 2022 Term of agreement: Open Details: Noxopharm Limited Annual salary of $410,000 plus superannuation of 10%. Notice period of 90 days by Executive or the Company. Key management personnel have no entitlement to termination payments in the event of removal for misconduct.
RkJQdWJsaXNoZXIy MjE2NDg3